INTRODUCTION
Metabolism plays a key role in the origin or progression of many diseases, including neurodegenerative diseases, diabetes, and cancer (1) (2) (3) (4) . Clinicians and patients would therefore benefit from a readily available noninvasive imaging modality that can reveal detailed meta bolic information. Despite great research progress in recent decades, metabolic imaging options are currently very limited in the clinic. The widely used magnetic resonance imaging (MRI) provides excellent anatomical detail and is nonradioactive but cannot image active meta bolism. Proton magnetic resonance spectroscopic imaging (MRSI) can map metabolite levels, but metabolite concentrations are only one aspect of metabolism and do not necessarily reflect the activity of a metabolic pathway (5) . Metabolic fluxes in humans have been studied using 13 C magnetic resonance spectroscopy (MRS) combined with administration of 13 Clabeled substrates to observe downstream 13 Clabeled metabolites (6) . However, because of its intrinsically low sensitivity, 13 C MRS in vivo has been restricted to relatively large single volumes. Both indirectly detecting 13 C through 1 H[ 13 C] MRS and using hyperpolarized 13 C are successful approaches that largely cir cumvent the low sensitivity of 13 C MRS (7, 8) . Yet, both of these methods are technically complex, which may prevent their development into a widespread technique. GlucoCEST is potentially easier to implement in the clinic, yet this technique does not provide direct information on glucose metabolism (9, 10) . At the moment, this leaves clinicians with positron emission tomography (PET) as the only available method for metabolic imaging. In the clinic, the most commonly available metabolic substrate for PET is the glucose analog 2 18 Ffluoro2 deoxydglucose ( 18 FDG), which provides highresolution maps of glucose uptake but does not inform on glucose metabolism. In addi tion, 18 FDG is radioactive, which is a limitation when repetitive scan ning is required such as in evaluating disease progression. Clearly, there is a demand for a more comprehensive, nonradioactive, and easily implementable approach to imaging metabolism.
Here, we present a novel approach that meets the current needs for metabolic imaging. Like H as a tracer for investigating metabolism precedes the discovery of nuclear magnetic resonance (11). More recently, 2 H MRS was used to study wholebrain metabolism at ultrahigh field in rats (12) , and deutera tion of 13 Clabeled glucose significantly improves the magnetization lifetime of 13 C in hyperpolarized 13 C imaging (13, 14) . However, to the best of our knowledge, metabolic imaging based on 2 H MRS in vivo has not yet been reported. Here, we show how deuterium metabolic imaging (DMI), which is based on 2 H MRSI, can noninvasively gen erate metabolic maps with high spatiotemporal resolution and display the metabolic fate of several 2 Hlabeled substrates. DMI revealed differences in metabolism of [6,6′ 2 H 2 ]glucose and [ 2 H 3 ]acetate be tween normal brain and tumor tissue in a rat glioma model. In the same animal model, DMI also detected therapyinduced changes in glucose metabolism. This method was straightaway translated to humans, and we present metabolic maps acquired after oral administration of [6,6′ 2 H 2 ]-labeled glucose in healthy human subjects and in patients diagnosed with a glioblastoma multiforme (GBM) brain tumor. To demonstrate the method's robustness and sensitivity in noncerebral tissues, we administered deuteriumlabeled glucose and then used DMI to map 2 Hlabeled glycogen in both rat and human livers.
RESULTS

In vivo
2
H NMR DMI is based on 2 H nuclear magnetic resonance (NMR), which, through the H spectrum acquired from the human brain at a lower magnetic field strength (4 T versus 11.7 T) has an inherently lower spectral resolution, resulting in partially overlap ping peaks. However, the peaks are sufficiently separated for reliable quantification through spectral fitting. Deuterium NMR spectra ac quired in rat and human livers, depicted in Fig. 1F Hlabeled glucose, lactate, and Glx were quantified by peak fitting, and the resulting amplitudes represented as colorcoded DMI maps were overlaid onto an anatomical MR image (Figs. 2 to 4) . Oxida tive glucose metabolism is represented by the labeled Glx that ap peared to be relatively homogeneous in normal brain, with a marked decrease in the tumor lesion (normal brain, 1.5 ± 0.3 mM; n = 45 voxels; tumor, 0.7 ± 0.2 mM; P < 0.001; n = 8 voxels). The glucose and Glx sig nals from normalappearing brain, on the basis of contrastenhanced MRI (Fig. 2) , were in agreement with the DMI data acquired in healthy rats (glucose: normalappearing brain in tumorbearing rats, 1.5 ± 0.3 mM (n = 45 voxels); normal brain in healthy rats, 1.7 ± 0.7 mM (n = 81 voxels); P = 0.17; Glx: normalappearing brain in tumor bearing rat, 1.5 ± 0.3 mM; normal brain in healthy rat, 1.5 ± 0.5 mM; P = 0.64). DMI showed lower levels of deuterated glucose and higher levels of labeled lactate in tumors compared to normal brain (lactate: tumor, 1.3 ± 0.4 mM; n = 8 voxels; normal brain, 0.6 ± 0.2 mM; P < 0.001; n = 45 voxels; glucose: tumor, 1.2 ± 0.1 mM; normal brain, 1.5 ± 0.3 mM; P = 0.001; see Fig. 2 ). The observed labeling in the rat brain tumor is consistent with both high glucose uptake and a high rate of glycolysis, which lowers the intracellular glucose level and pro duces lactate instead of oxidizing the glucosederived pyruvate. This meta bolic phenotype was first described by Otto Warburg and is well known in cancer biology (18, 19) . Because the levels of labeled lactate and Glx represent glycolytic and oxidative metabolism, respectively, the ratio of lactate over Glx can be seen as representing the Warburg effect. DMI can consequently be used to spatially map the Warburg effect and showed greatly elevated contrast in tumor lesions (tumor, 1.8 ± 0.8; n = 8 voxels; normal brain, 0.4 ± 0.1; P < 0.001; n = 45 voxels; fig. S2 ), which is five times lower than the 2 Hlabeled lactate level observed with DMI in the brain tumor region. These data confirm that the bulk of the labeled lactate ob served in the tumor region was produced locally and not transported from the blood.
To explore whether DMI could provide an imaging biomarker for therapy response, we treated gliomabearing rats with dichloro acetate (DCA). DCA stimulates pyruvate dehydrogenase, which facilitates pyruvate flux into mitochondria for subsequent oxidation, thereby partially reversing the Warburg effect. Treatment with DCA 90 min before [6,6′ 2 H 2 ]glucose infusion and subsequent DMI ap peared to reduce both the area and intensity of the lactate/Glx ratio ( fig. S3 ). Hence, DMI provided a fast, noninvasive way to image a metabolic drug's effects on glucose metabolism in the brain tumor.
Isotopically labeled acetate has been used as a metabolic substrate to investigate metabolism in animal and human brain and liver (16, 20) . Acetate is converted to acetyl-coenzyme A (CoA) and further meta bolized in the tricarboxylic acid (TCA) cycle, labeling Glx through fast exchange with ketoglutarate. Unlike glucose, acetate does not require pyruvate dehydrogenase activity to enter the TCA cycle. In stead, acetate can be considered a surrogate for fatty acid oxidation. The map of labeled Glx in a gliomabearing rat shows a relatively ho mogeneous distribution of acetate oxidation in normalappearing brain tissue. By contrast, tumor tissue showed higher levels of labeled acetate and lower levels of Glx labeling (acetate, 2.9 ± 0.3 mM; Glx, 0.6 ± 0.2 mM) than normal brain (acetate, 1.0 ± 0.4 mM; Glx, 0.9 ± 0.2 mM; n = 1; fig. S4 ). These results indicate differences in tumor metabolism of acetate compared to normal brain tissue.
DMI of steady-state glucose metabolism in human brain
We performed DMI on the brains of healthy control subjects who ingested [6,6′ 2 H 2 ]glucose (0.75 g/kg body weight). To cover a large part of the brain, we collected DMI data using a 3D grid of 2 × 2 × 2 cm 3 voxels, and the peak amplitudes of glucose and metabolites are shown as colorcoded concentration maps (Fig. 3) . The distribution of labeled Glx seemed more prominent in the cortices, rich in gray matter, and lower in regions that, on the basis of anatomical location, contain mostly cerebrospinal fluid. These levels concur with individual 2 H NMR spectra from voxels positioned in the cortex and ventricles ( fig. S5 ).
We also performed DMI 60 to 75 min after oral intake of [6,6′ 2 H 2 ]glucose (0.60 g/kg) ( Fig. 4 and fig. S6 ), on two patients diag nosed with GBM. Figure 4 shows the DMI data collected in patient 1. In normalappearing brain (for example, a region in the occipital lobe), DMI showed a fairly homogeneous distribution of labeled glucose and Glx, similar to the data from a healthy subject (Fig. 3 ). The concentrations of 2 Hlabeled glucose and Glx in normal brain tissue were slightly lower in the patient, most likely because of the smaller oral glucose dose (0.60 g/kg versus 0.75 g/kg in healthy controls). H 2 ]glucose infusion. Spectra shown in red had sufficient signal for further processing, whereas those in blue were discarded. Experimental 2 H NMR spectra from (C) normal-appearing brain and (D) tumor lesion, with the spectral fitting results for the total spectrum, individual peaks, and fitting residue shown below. Note that localized spectra have higher spectral resolution than nonlocalized spectra ( Fig. 1 ), a consequence of the smaller 8-l volumes' inherent increased magnetic field homogeneity. (E to H) DMI maps of
In the lesion area (right frontal lobe), labeled Glx was not observed, whereas 2 Hlactate and lactate/Glx maps show striking contrast in both patients ( Fig. 4 and fig. S6 ). These metabolic maps are remarkably similar to the DMI data acquired in the rat model of GBM and demonstrate the distinct differences in glucose metabolism between tumor and normal brain (Fig. 2) .
DMI of liver glycogen
The versatility of DMI for imaging metabolism in organs other than the brain is exemplified by imaging labeled glycogen in the liver. As the primary organ for storing glucose in the form of glycogen, the liver plays a major role in wholebody glucose homeostasis. Figure 5D displays a DMIbased map of labeled glycogen 2 hours after intravenous injection of [6,6′ 2 H 2 ]glucose in a healthy rat. Estimated concentra tion based on the naturally abundant deuterated water (8.9 mM; see Materials and Methods) indicates levels of labeled glycogen + glucose of 2.7 ± 0.3 mM. No other labeled metabolites are detected in the 2 H NMR spectra, which indicates that the liver is predominantly storing glucose instead of using it as an oxidative fuel. However, the con centration of glutamate in rat liver has been reported to be 2 to 3 mM, which is several times lower than in the brain (21) . The low level of 2 H labeling and the small glutamate pool size could result in deuterium labeled glutamate levels that are too low to detect with the current 2 H volume RF coil setup. We applied a similar approach to healthy human subjects by using a surface RF coil positioned on the liver's lateral aspect. DMI following oral intake of [6,6′ 2 H 2 ]glucose also revealed labeled glycogen in human liver, which is homogeneously distributed within the RF coil's field of view (Fig. 5 
DISCUSSION
Our results show that DMI, which combines 2 H MRSI with adminis tration of deuteriumlabeled substrates, can distinguish between normal and aberrant metabolism in vivo. We demonstrated DMI's potential by mapping the metabolism of either 2 Hlabeled glucose or acetate in the brain and liver of animal models and human subjects. The DMIbased data allowed 3D visualization of in vivo metabolism with technically simple and robust methods that can be implemented on (Fig. 2) most clinical MRI scanners. Accordingly, we believe that DMI's ca pacity to image metabolism can be of great clinical benefit in a variety of disease settings.
The DMI map of labeled glucose in a patient with GBM showed minimal contrast between the tumor lesion and normal brain due to high glucose uptake in both tissue types, particularly in gray matter. This is a welldescribed challenge when using 18 FDGPET to evalu ate brain tumor glucose metabolism (22) . Because DMI can visualize metabolism beyond glucose uptake, maps of 2 Hlabeled Glx and lactate show striking contrast. The lower levels of labeled Glx and higher levels of labeled lactate in the tumor, observed in both the animal model and the patients with GBM (Figs. 2 and 4 fig. S4 ). Acetate is taken up via the monocarboxylic transporter 1 (MCT1), which is expressed in RG2 glioma and a potential therapeutic target in some cancers (23) (24) (25) . These data suggest that 2 Hlabeled acetate levels, as measured with DMI within the glioma, could serve as a noninvasive biomarker of MCT1 expression. Thus, DMI could be used to evaluate the efficacy of a therapy targeting MCT1. However, the RG2 rodent tumor model also has a compromised bloodbrain barrier that could facilitate increased acetate uptake independently of MCT1. In addi tion, the glutamate levels in the RG2 tumor are typically lower than in adjacent normalappearing brain (25) . A smaller Glx pool size could result in a lower absolute level of deuterated Glx and thus affect the image contrast observed with DMI.
We also used DMI to evaluate liver glycogen labeling after [6,6′ 2 H 2 ]glucose administration, therefore demonstrating this technique's applicability in organs other than the brain. As with the brain, DMI of the liver is methodologically simple but robust. DMI of liver gly cogen storage will be valuable for studying the liver's role in condi tions such as type 2 diabetes and nonalcoholic fatty liver disease. DMI of the liver could also be applied dynamically to measure the rate of glycogen turnover. Without administration of a 2 Hlabeled substrate, DMI merely detects the 0.0115% naturally abundant 2 H in the large water pool (~10 mM in the brain) and, in some cases, a small signal from lipids (for example, Fig. 1F , rat liver) (15) . DMI therefore requires neither additional RF pulses for water suppression nor outer volume suppres sion to exclude large contaminating signals from adjacent lipid tissue. Further, DMI is minimally affected by magnetic field inhomogeneity because of its low NMR frequency and the intrinsically broad peaks of 2 H NMR. In addition, because 2 H NMR spectra only contain a few metabolite peaks, some minimal line broadening does not lead to large peak overlap. DMI's relative invulnerability to magnetic field inhomo geneity is seen in individual 2 H NMR spectra of the frontal lobe and tumor areas with ironcontaining hemosiderin (Fig. 4 and fig. S5 ). Together, these aspects make DMI easy to implement and perform, in contrast to technically challenging 1 H and 13 C MRS(I) (7), there by broadening its applicability and establishing DMI's potential.
The feasibility of DMI depends on its sensitivity, which is influ enced by the gyromagnetic ratio and magnetic moment of the 2 H spin, 
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as well as the relaxation times of the 2 Hlabeled molecules. The gyro magnetic ratio of 2 H is 6.5 times lower than that of 1 H, which is the nucleus with the highest NMR sensitivity. This disadvantage is partly offset by the larger magnetic moment generated by 2 H, which has a spin quantum number of 1, compared to nuclei, including 1 H, with spin ½. Deuterium's relaxation parameters favor rapid scanning while retaining reasonable spectral resolution. The deuterium T 1 relaxation times of 2 Hlabeled metabolites are approximately 10 times shorter than the cor responding proton T 1 values, which, for equivalent scan times, would translate in a √10 increase in signaltonoise ratio (SNR). Meanwhile, the T 2 and T 2 * relaxation times are relatively long compared to T 1 , thereby further enhancing the detection of 2 Hlabeled compounds. Similar to 17 O NMR, the SNR of 2 H has an approximate quadrat ic relation with magnetic field strength, which implies that, at 7 T, the SNR would be three times higher than at 4 T (26). We foresee that DMI can be easily implemented at 7 T, and a spatial resolution approaching 1 × 1 × 1 cm 3 can be achieved using an optimized RF coil. Applying NMR in vivo at ultrahigh field can be challenging be cause the U.S. Food and Drug Administration (FDA) guidelines for the specific absorption rate (SAR). The SAR of DMI at 4 T was esti mated at 0.16 W/kg (see Materials and Methods), which is much lower than the FDA guideline of 3 W/kg, and thus, it is straightforward to implement DMI at 7 T. RF inhomogeneity is another complication at 7 T but will not pose a problem because of the low frequency at which DMI operates (45.7 MHz at 7 T).
Both deuteriumlabeled substrates and water have been used in clinical research for many years (27, 28) . The amounts of 2 H admin istered for DMI (~1 g of 2 H for a 70kg subject) are lower than those used in other research applications (28) . Studies in humans focused on cells or molecules with low metabolic turnover rates have used D 2 O doses that result in 400 times more 2 H loading than a typical DMI study (29, 30) . The amount of deuterium used for a DMI study is thus orders of magnitude lower than that used in other research applications, for which the dose of 2 H has been considered safe (27) (28) (29) (30) . In this first implementation of DMI, the focus was limited to data acquisition during isotopic steady state. DMI could, in the future, also be applied dynamically during labeled substrate infusion to assess meta bolic turnover. We focused initially on steadystate metabolism because its simplicity favors rapid implementation in the clinic. A limitation of the DMI application in liver was the overlapping peaks of [6 (31) . To cor rect the labeling of Glx for label loss at the citrate synthethase step of the TCA cycle, we used a theoretically derived factor. Future studies could be performed to confirm these factors by welldesigned in vivo experiments. However, using the currently known correction factors for label loss, the concentration of 2 Hlabeled Glx is very close to the concentrations of labeled Glx when using 13 Clabeled glucose in vivo in human brain. Therefore, the label loss correction factors deter mined in vivo are most likely to be close to the theoretical value (32, 33) . Another factor in the determination of absolute 2 H concentration in vivo is the value of the natural abundance of 2 H in tissue water. We used the literature value for natural abundance of 2 H in water on Earth (15) . Determination of the range of natural abundance 2 H levels in tissue water would be beneficial for its use as an internal con centration standard.
Using deuterium to study metabolism was suggested as early as 1935 (11). Global, nonlocalized 2 H MRS has been used at ultrahigh magnetic fields to quantify metabolism in a wide range of settings including excised rabbit cornea (34), wholebody mouse lipid syn thesis (35) , and rat brain in vivo (12) . MRI of 2 H has also been ex plored, particularly to measure blood flow and perfusion (36-38). DMI now combines the chemical specificity of 2 H NMR with the spatial localization of MRI to produce noninvasively metabolic maps in human tissue. Implementing DMI on existing 3 T clinical MRI scanners only requires minimal technical modifications and the acquisition of an RF coil that operates at the 2 H NMR frequency (19.6 MHz). The exten sive availability of 3 T MRI scanners should facilitate DMI to become a widespread MRI modality for clinical metabolic imaging.
MATERIALS AND METHODS
MR systems Animal and high-resolution NMR systems
Animal studies were performed on an 11.7 T Magnex magnet (Magnex Scientific Ltd.) interfaced to a Bruker Avance III HD spec trometer running on ParaVision 6 (Bruker Instruments). The system was equipped with 9.0cmdiameter Magnex gradients capable of switching 440 mT/m in 180 s and 0.5kW RF amplifiers for RF transmission and reception for MRI and shimming during brain studies were performed with two orthogonal 20mm surface coils driven in quadrature and tuned to the proton NMR frequency (499.8 MHz). Deuterium RF transmission and reception were achieved with a two turn 14mmdiameter surface coil tuned to 76.7 MHz and integrated with the proton RF coil according to the design described by Adriany and Gruetter (39).
Liver studies were performed with a 5.9cmdiameter proton volume coil (6.1 cm in length) for MRI and shimming and a 5.0cmdiameter deuterium volume coil (6.1 cm in length) for Brain studies were conducted with a 28.5cmdiameter transverse electromagnetic (TEM) volume coil tuned to the proton frequency (170. H coils ar rayed in quadrature for MRI and shimming was used for all human liver studies.
Human subjects
All human studies were approved by the Yale University Institutional Review Board. Healthy control subjects (n = 2) and two patients di agnosed with GBM were recruited to participate in the DMI study. The patients (male; 63 and 67 years old) with GBM had undergone a subtotal resection of the lesion 9 and 1 month(s) before the DMI study. One patient was undergoing treatment on an experimental protocol involving nivolumab or placebo combined with the standard ofcare chemoradiation with temozolomide, followed by adjuvant temozolomide. The other patient had only received surgery before the DMI study.
H 3 ]acetate was dissolved in water at a concentration of 2 M and was infused as described for glucose, resulting in a total of 2 g/kg body weight of [ 2 H 3 ]acetate infused during a 120min study. All an imal procedures were approved by the Yale University Institutional Animal Care and Use Committee.
Animal experiments
Fischer 344 rats (n = 9) were used for DMI experiments in healthy brain, liver, and glioma after implantation of RG2 cells. The glioma model was established as described previously (25) . In short, RG2 glioma cells (American Type Culture Collection) were grown in T75 flasks using standard cell culture conditions (37°C and 5% CO 2 ). RG2 cells were harvested, and ~1250 cells suspended in 5 l of serumfree, lowglucose Dulbecco's modified Eagle's medium (DMEM) were in jected in the brain of anesthetized rats.
For DMI experiments, rats were anesthetized with isoflurane using ~60% O 2 and ~40% N 2 O delivered through a nose cone. A heating pad or heated air was used to maintain body temperature at ~37°C. Breath ing, heart rate, and blood oxygenation parameters were monitored continuously using a pulse oximeter probe (MouseOx, Starr Life Sciences Corp.) on the foot.
Blood was sampled from an arterial catheter placed in the femoral artery (25) . The blood sample was centrifuged (5000 rpm for 5 min), and the plasma was stored at −80°C for later processing. Plasma sam ples were prepared for highresolution NMR by adding 160 l of methanol to 80 l of plasma to precipitate plasma proteins. This mix ture was incubated at −20°C for 20 min, followed by centrifugation at 10,000 rpm for 30 min at 4°C. The supernatant was transferred to a 2ml vial, and the methanol was evaporated under nitrogen using a TurboVap LV (Biotage) at 45°C for ~60 min. The sample was resus pended in 600 l of a mixture of water containing phosphate buffer (100 mM), D 2 O (10%), sodium formate, and imidazole as a chemical shift reference and internal concentration standard, respectively.
In vitro experiments
Rat gliosarcoma cells (9L, American Type Culture Collection) were cultured in T75 flasks using standard cell culture conditions (37°C and 5% CO 2 ). For the 13 C/ 2 H labeling experiments, cells were washed with phosphatebuffered saline and incubated with DMEM contain ing 100% [6 13 C]glucose or [6 13 C,6,6′ 2 H 2 ]glucose (SigmaAldrich, Isotec). After 6 hours, the incubation medium was collected, [2 13 C] glycine was added as an internal concentration standard, and the samples (5 ml) were freezedried on a lyophilizer (Labconco). Freeze dried samples were prepared for NMR analysis by adding 600 l of a mixture of water containing phosphate buffer (100 mM), D 2 O (10%), sodium formate, and imidazole as a chemical shift reference and internal concentration standard, respectively.
MR signal acquisition
For human brain studies, subjects were positioned supine within the combined H volume coil for liver studies. Body temperature was maintained at 37°C with a heated water pad (brain studies) or heated air (liver studies). For brain studies, the acquisition of anatomical MR images was followed by 3D B 0 mapping (second order SH shimming), resulting in approximately 25 to 30 Hz across a 7 mm × 5 mm × 10 mm = 750l volume. In brain tumor-bearing rats, T 1 weighted images were acquired after intravenous or intra peritoneal injection of 200 l of the T 1 contrast agent gadopentetate dimeglumine (Magnevist, Bayer). For liver studies, MR image acqui sition, as well as iterative shimming of linear SH shims, was respiration gated. The magnetic field homogeneity across an oblique 10 mm × 18 mm × 5 mm = 900l volume was typically in the 60 to 90Hz range, as measured from the water linewidth. DMI data were always acquired without respiratory triggering.
H MR signal acquisition was achieved with a pulseacquire se quence extended with 3D phaseencoding gradients during the ini tial 1.1 ms (animal) or 2.7 ms (human) following excitation. For brain and human liver studies, signal excitation was achieved with a 90° rectangular RF pulse of 50s (animal) or 500s (human) dura tion. For animal liver studies, signal excitation was achieved with a 2.0ms Shinnar-Le Roux RF pulses (90°; band width, 3.0 kHz), se lecting a 25mmthick transverse slab to minimize artifacts due to heart pulsations (41).
Human T 1 , T 2 , and T 2 * measurements T 1 values of water, glucose, Glx, and lactate were estimated on the basis of a threeparameter fit of the signal amplitude acquired using a nonlocalized inversionrecovery method with 12 logarithmatically spaced inversion times between 10 and 2560 ms and a TR of 2560 ms (42). The inversionrecovery experiments were performed using an adiabatic inversion pulse to assure homogeneous excitation.
Global T 2 measurements were performed with a nonlocalized spin echo sequence with 12 different echo times between 6 and 400 ms. The decaying signal amplitudes were fit with a monoexponential function in case of labeled glucose, Glx, and lactate and a biexponen tial function for affected 3 kg (60% of a 5kg human head). This estimation resulted in a SAR of 0.16 W/kg. 2 Hlabeled metabolites were ana lyzed using MannWhitney U tests in SPSS 24 (IBM). Metabolite con centrations were grouped on the basis of tissue type (normal brain or tumor) by manually drawn regions based on anatomical MRI data and were combined for all animals. The choice for a nonparametric test was based on the differences in data distribution inherent to the much larger number of voxels of normal brain compared to tumor tissue. P < 0.05 was considered statistically significant.
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